In contrast, Myr (300 mg/kg) treatment significantly reduced T2D-induced augmentation of ROS (p < 0.01), NO (p < 0.01), NADPH oxidase (p < 0.01), TBRAS (p < 0.05), and carbonylated protein (p < 0.05) levels in the renal tissue of T2D rats as compared to T2D control rats (Figure 10a–e). This evidence concerns the gene FMO5 and type 2 diabetes mellitus.